-
Mashup Score: 0
The FDA granted accelerated approval to pacritinib for treatment of adults with myelofibrosis and thrombocytopenia.The approval applies to use of the agent by patients with intermediate- or high-risk primary or secondary myelofibrosis with a platelet count less than 50 x 109/L.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA granted accelerated approval to pacritinib for treatment of adults with myelofibrosis and thrombocytopenia.The approval applies to use of the agent by patients with intermediate- or high-risk primary or secondary myelofibrosis with a platelet count less than 50 x 109/L.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎙"The approval of Vonjo establishes a new standard of care for [patients with myelofibrosis] suffering from cytopenic myelofibrosis," says John Mascarenhas, MD of @TischCancer @IcahnMountSinai READ more about the FDA approval: https://t.co/kHtMHJdRDP #oncology #pacritinib https://t.co/mpVJCLTcL0
-
-
Mashup Score: 1
John Mascarenhas, MD, Mount Sinai, New York, NY, gives an overview of an ongoing Phase III PACIFICA study (NCT03165734) of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
John Mascarenhas of @IcahnMountSinai gives an update on the PACIFICA study of #Pacritinib versus physician’s choice in patients with primary or secondary #Myelofibrosis. Watch: 👉https://t.co/yW7QRUrRGh👈 @EHA_Hematology #EHA2021 @VJHemOnc #HemOnc #MPNsm
-
-
Mashup Score: 0Pacritinib activity against myelofibrosis - 4 year(s) ago
John Mascarenhas, MD, of of the Icahn School of Medicine at Mount Sinai, New York, NY, discusses pacritinib, a JAK2…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#TxMPN2020 continues with John Mascarenhas from @MountSinaiNYC discussing #Pacritinib Click for our interview with him @VJHemOnc: 👉https://t.co/q2SJpTQYVG👈 @UTHealthSAMDA @LeukemiaMDA @OncoAlert #MPN #MPNsm #Leusm https://t.co/bPNbHl95vK
-
🎙"The approval of Vonjo establishes a new standard of care for [patients with myelofibrosis] suffering from cytopenic myelofibrosis," says John Mascarenhas, MD of @TischCancer @IcahnMountSinai READ more about the FDA approval: https://t.co/vd9Ix1ILeg #oncology #pacritinib https://t.co/DKTz5GUtzW